{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T12:26:45Z","timestamp":1772886405004,"version":"3.50.1"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/ http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Background and aims:<\/jats:title>\n            <jats:p>Hepatocellular carcinoma (HCC) is the third-most lethal malignant tumor worldwide. The rapid development of immunotherapy utilizing immune checkpoint inhibitors for advanced HCC patients has been witnessed in recent years, along with numerous randomized clinical trials demonstrating the survival benefits for these individuals. This systematic review and meta-analysis aimed to identify specific clinico-pathological characteristics of advanced HCC patients that may lead to preferable responses to immunotherapy in terms of overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The included clinical trials were retrieved from PubMed, Embase, the Cochrane library, and the Web of Science databases published in English between 1 January 2002 and 20 October 2022. A systematic review and meta-analysis for first-line and second-line phase II\/III studies were conducted on immunotherapy for patients with advanced HCC by using OS as the primary outcome measure, and PFS and ORR as the secondary outcome measures to obtain clinico-pathological characteristics of patients which might be preferable responses to programmed death-1 (PD-1) and programmed cell death-Ligand 1 (PD-L1) inhibitors. Toxicity and specific treatment-related adverse events (TRAEs) were also determined.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>After screening 1392 relevant studies, 12 studies were included in this systematic review and meta-analysis to include 5948 patients. Based on the analysis of interaction, the difference in OS after first-line immunotherapy between the subgroups of viral hepatitis [hazard ratio (HR)=0.73 vs 0.87, <jats:italic toggle=\"yes\">P<\/jats:italic> for interaction=0.02] and macrovascular invasion and\/or extrahepatic spread (HR=0.73 vs 0.89, <jats:italic toggle=\"yes\">P<\/jats:italic> for interaction=0.02) were significant. The difference in PFS between the subgroups of viral hepatitis was highly significant (pooled HR=0.55 vs 0.81, <jats:italic toggle=\"yes\">P<\/jats:italic> for interaction=0.007). After second-line immunotherapy, the difference in ORR between the subgroups of Barcelona Clinic Liver Cancer was significant (pooled ES=0.12 vs 0.23, <jats:italic toggle=\"yes\">P<\/jats:italic> for interaction=0.04). Compared with PD-L1 inhibitors, PD-1 inhibitors may have a higher probability to cause TRAEs. Diarrhea, increased aspartate aminotransferase, and hypertension were the top three TRAEs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This systematic review and meta-analysis represents the first pilot study aimed at identifying crucial clinico-pathological characteristics of patients with advanced HCC that may predict favorable treatment outcomes in terms of OS, PFS, and ORR to immunotherapy. Findings suggest that patients with viral hepatitis positivity (especially hepatitis B virus) and macrovascular invasion and\/or extrahepatic spread may benefit more in OS when treated with PD-1\/PD-L1 immune checkpoint inhibitors.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/js9.0000000000000652","type":"journal-article","created":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T11:01:37Z","timestamp":1692529297000},"page":"3590-3601","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Clinico-characteristics of patients which correlated with preferable treatment outcomes in immunotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis"],"prefix":"10.1097","volume":"109","author":[{"given":"Yani","family":"Wang","sequence":"first","affiliation":[{"name":"Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, the First Hospital Affiliated to AMU (Southwest Hospital)"},{"name":"Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanyee","family":"Lau","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, SAR, People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichen","family":"Tian","sequence":"additional","affiliation":[{"name":"Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, the First Hospital Affiliated to AMU (Southwest Hospital)"},{"name":"Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongrong","family":"Lei","sequence":"additional","affiliation":[{"name":"Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, the First Hospital Affiliated to AMU (Southwest Hospital)"},{"name":"Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"Wang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Xia","sequence":"additional","affiliation":[{"name":"Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, the First Hospital Affiliated to AMU (Southwest Hospital)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,11]]},"reference":[{"key":"R1-20250824","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"R2-20250824","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20250824","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2217\/fon-2020-0758","article-title":"Systemic therapy of advanced hepatocellular carcinoma","volume":"17","author":"Galle","year":"2021","journal-title":"Future Oncol"},{"key":"R4-20250824","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"R5-20250824","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"R6-20250824","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"R7-20250824","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"The Lancet"},{"key":"R8-20250824","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid open"},{"key":"R9-20250824","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"R10-20250824","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-21-3275","article-title":"Alpha-Fetoprotein as a potential surrogate biomarker for Atezolizumab + Bevacizumab treatment of hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"R11-20250824","doi-asserted-by":"crossref","first-page":"808101","DOI":"10.3389\/fimmu.2022.808101","article-title":"C-reactive protein levels predict responses to PD-1 inhibitors in hepatocellular carcinoma patients","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"R12-20250824","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jhep.2016.02.021","article-title":"Mechanisms of HBV-induced hepatocellular carcinoma","volume":"64","author":"Levrero","year":"2016","journal-title":"J Hepatol"},{"key":"R13-20250824","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"88","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"R14-20250824","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R15-20250824","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R16-20250824","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (minors): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"R17-20250824","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.annonc.2019.12.001","article-title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced\/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO","volume":"31","author":"Chen","year":"2020","journal-title":"Ann Oncol"},{"key":"R18-20250824","doi-asserted-by":"crossref","first-page":"100117","DOI":"10.1016\/j.esmoop.2021.100117","article-title":"Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring","volume":"6","author":"Gyawali","year":"2021","journal-title":"ESMO Open"},{"key":"R19-20250824","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/1078-0432.CCR-20-2571","article-title":"Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial","volume":"27","author":"Xu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"R20-20250824","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol"},{"key":"R21-20250824","doi-asserted-by":"crossref","first-page":"S1401","DOI":"10.1016\/j.annonc.2022.08.032","article-title":"LBA35 camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): a randomized, phase III trial","volume":"33","author":"Qin","year":"2022","journal-title":"Ann Oncol"},{"key":"R22-20250824","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"key":"R23-20250824","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"R24-20250824","doi-asserted-by":"crossref","first-page":"S1402","DOI":"10.1016\/j.annonc.2022.08.033","article-title":"LBA36 final analysis of RATIONALE-301: randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma","volume":"33","author":"Qin","year":"2022","journal-title":"Ann Oncol"},{"key":"R25-20250824","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2022.02.009","article-title":"Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","volume":"167","author":"Kudo","year":"2022","journal-title":"Eur J Cancer"},{"key":"R26-20250824","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000527175","article-title":"Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, phase 2 trial","volume":"12","author":"Ren","year":"2022","journal-title":"Liver Cancer"},{"key":"R27-20250824","doi-asserted-by":"crossref","first-page":"e204564","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the Checkmate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"R28-20250824","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S1470-2045(21)00252-7","article-title":"Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2\u20133 study","volume":"22","author":"Ren","year":"2021","journal-title":"Lancet Oncol"},{"key":"R29-20250824","doi-asserted-by":"crossref","first-page":"S1401","DOI":"10.1016\/j.annonc.2022.08.031","article-title":"LBA34 primary results from the phase III LEAP-002 study:lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)","volume":"33","author":"Finn","year":"2022","journal-title":"Ann Oncol"},{"key":"R30-20250824","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41419-021-03553-7","article-title":"Autophagy, an accomplice or antagonist of drug resistance in HCC?","volume":"12","author":"Wu","year":"2021","journal-title":"Cell Death Dis"},{"key":"R31-20250824","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"R32-20250824","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1053\/j.gastro.2021.06.008","article-title":"Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002\u20132020)","volume":"161","author":"Haber","year":"2021","journal-title":"Gastroenterology"},{"key":"R33-20250824","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"key":"R34-20250824","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-021-03233-8","article-title":"Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH","volume":"592","author":"Dudek","year":"2021","journal-title":"Nature"},{"key":"R35-20250824","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.29486","article-title":"Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis","volume":"67","author":"Finn","year":"2018","journal-title":"Hepatology"},{"key":"R36-20250824","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/1568009619666191114110359","article-title":"Anti-VEGF\/VEGFR2 monoclonal antibodies and their combinations with PD-1\/PD-L1 inhibitors in Clinic","volume":"20","author":"Gao","year":"2020","journal-title":"Curr Cancer Drug Targets"},{"key":"R37-20250824","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"R38-20250824","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"R39-20250824","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41392-020-0187-x","article-title":"The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects","volume":"5","author":"Tang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"R40-20250824","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"key":"R41-20250824","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"key":"R42-20250824","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1084\/jem.20130790","article-title":"RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance","volume":"211","author":"Xiao","year":"2014","journal-title":"J Exp Med"},{"key":"R43-20250824","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"key":"R44-20250824","doi-asserted-by":"crossref","first-page":"10691","DOI":"10.1073\/pnas.0307252101","article-title":"PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells","volume":"101","author":"Latchman","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R45-20250824","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1200\/JCO.20.00808","article-title":"Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma","volume":"38","author":"Finn","year":"2020","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000000652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T19:07:37Z","timestamp":1756062457000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000000652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000000652","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]},"assertion":[{"value":"2023-05-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}